The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly become a global public health threat. The efficacy of several repurposed drugs has been evaluated in clinical trials. Among these drugs, a second-generation antiandrogen agent, enzalutamide, was proposed because it reduces the expression of transmembrane serine protease 2 (TMPRSS2), a key component mediating SARS-CoV-2-driven entry, in prostate cancer cells. However, definitive evidence for the therapeutic efficacy of enzalutamide in COVID-19 is lacking. Here, we evaluated the antiviral efficacy of enzalutamide in prostate cancer cells, lung cancer cells, human lung organoids and Ad-ACE2-transduced mice. Tmprss2 knockout significantly inhibited SARS-CoV-2 infection in vivo. Enzalutamide effectively inhibited SARS-CoV-2 infection in human prostate cells, however, such antiviral efficacy was lacking in human lung cells and organoids. Accordingly, enzalutamide showed no antiviral activity due to the AR-independent TMPRSS2 expression in mouse and human lung epithelial cells. Moreover, we observed distinct AR binding patterns between prostate cells and lung cells and a lack of direct binding of AR to TMPRSS2 regulatory locus in human lung cells. Thus, our findings do not support the postulated protective role of enzalutamide in treating COVID-19 through reducing TMPRSS2 expression in lung cells. Enzalutamide, an approved drug for prostate cancer, acts on TMPRSS2 expression, a key mediator for SARS-CoV-2 infection. Here, the authors characterize the anti-SARS-CoV-2 effects of Enzalutamide in prostate cancer cells, lung cancer cells, human lung organoids and in hACE2-transduced Tmprss2 knockout mice and show lack antiviral action in human lung cells and human lung organoids, likely due to the AR-independent TMPRSS2 expression in mouse and human lung epithelial cells.
【저자키워드】 SARS-CoV-2, Prostate cancer, Gene regulation, TMPRSS2, 【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, Efficacy, coronavirus, pandemic, SARS-COV-2 infection, drugs, clinical trials, antiviral activity, lung cancer, severe acute respiratory syndrome Coronavirus, anti-SARS-CoV-2, hACE2, Repurposed drug, Regulatory, cells, mice, human lung, antiviral efficacy, epithelial cells, Prostate cancer, enzalutamide, antiandrogen, organoids, TMPRSS, respiratory, transmembrane serine protease 2, in vivo, expression, binding, Prostate, Evidence, Cancer cells, mediator, Support, acute respiratory syndrome, Serine, locus, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, global public health, therapeutic efficacy, transmembrane serine protease, TMPRSS2 expression, protective role, treating COVID-19, human lung cells, antiviral action, lung cells, knockout mice, human lung organoids, Tmprss2 knockout, Effect, Cell, lung cell, lack, caused, significantly, evaluated, inhibited, approved, reducing, reduce, binding pattern, human lung cell, human lung organoid, 【제목키워드】 enzalutamide, mechanism, explain, organ-specific,